Latest News

BerGenBio plans IPO and partners with MSD

To activate the Axl kinase and transmit its signal to the cell nucleus, the GAS6 ligand has to bind externally and the energy carrier ATP (green) internally. Inhibitors (orange) prevent transmission of the signal, © MPI for Biochemistry


by tg

Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.

The IPO, underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets, includes a public offering to institutional and retail investors in Norway and Sweden, and a private placement to certain institutional investors internationally.

BerGenBio’s lead candidate BGB324 (formerly R-428), licensed from Rigel Pharmaceuticals in 2010, has passed Phase Ib testing in acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), and non-small cell lung cancer (NSCLC, in combination with erlonitib) patients. On the day of the IPO announcement, BerGenBio additionally said it will start two collaborative Phase II combination studies of BGB324 with Merck & Co’s PD-1 checkpoint inhibitor pembrolizumab this year in patients with adenocarcinoma (NSCLC) and and triple-negative breast cancer (TNBC). The clinical trials will be sponsored by BerGenBio while Merck will provide the trial with Keytruda. The rights to the study results will be shared. Financial details were not disclosed. Preclinical data from 2015 indicate that BGB324 showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition (CTLA-4, PD1) alone.

Axl kinase promotes cancer cell migration, epithelial-mesenchymal transition (EMT) and tumour cell proliferation as well as therapy resistance. The protein is overexpressed in the membranes of 60% of lung cancers, highly invasive breast cancers, and pancreatic cancer as well as in AML, where it serves as independent prognostic marker. Additionally, several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer, breast cancer resistant to EGFR inhibition, esophageal carcinoma, gastrointestinal stromal tumours, and AML. 

Besides its selective Axl kinase inhibitor, the Norwegian company also has an anti-Axl kinase antibody and an antibody drug conjugate (ADC) under preclinical development. Treatment responders are set to be stratified prior to therapy by a companion diagnostics test that measures Axl kinase expression.

Polyphor AG bags CHF19.3 in equity financing

Polyphor AG announced it has entered into an equity-linked financing arrangement with the French company IRIS to raise a gross amount of up to...

COVID-19: Roche and Regeneron join forces

Roche AG and Regeneron Therapeutics Inc said their collaboration is aimed at increasing the global supply of REGN-COV2, an experimental antibody...

BioGeneration Ventures closes BGV IV Fund at €105m

Investors into the oversubscribed BVG IV gathered existing actors — such as Bristol Myers Squibb, the European Investment Fund, and Schroder Adveq —...

Kurma Partners close diagnostics fund at €50m

Venture Capital company Kurma Partners SA (Paris/Munich) said the €50m committed to the Kurma Diagnostics Fund 2 (KDx2) will finance 15 companies...

Mabion to licence COVID-19 jab from Vaxine Pty Ltd

Currently, the Australian influenza vaccine and adjuvant specialist and the Polish protein drug maker have just inked a memorandum of understanding,...

MosaMeat NV bags US$55m financing

According to Mosa Meat NV, The $55m raised is part of a larger Series B funding round led by Luxembourg-based Blue Horizon Ventures, and co-financed...

VarmX bags €32m in Series B round

New investors LSP, Ysios Capital, INKEF Capital and Lundbeckfonden Ventures joined the financing round, with the contribution of existing investors...